RGRX - RegeneRx Biopharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2100
0.0000 (0.00%)
As of 2:13PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2100
Open0.2100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1930 - 0.2100
52 Week Range0.0700 - 0.3500
Volume5,934
Avg. Volume60,093
Market Cap27.616M
Beta (3Y Monthly)-0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0140
Earnings DateMay 20, 2019 - May 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    RegeneRx Partner Receives Patent for New Ophthalmic Formulation of Thymosin Beta 4

    ROCKVILLE, Md., May 16, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported today that its U.S. joint venture partner and Pan Asian licensee, GtreeBNT, has been granted a new U.S. patent for a method of preventing or treating dry eye syndrome by administering Tβ4 with non-active ingredients to provide improved pharmacodynamics.  Tβ4 is the active component of RGN-259, currently in separate phase 3 clinical trials for dry eye syndrome and neurotrophic keratitis.  The expiry of this new patent is 2035. Dry eye syndrome is a common condition affecting millions of people throughout the world.  It is a multi-factorial disorder where loss of homeostasis of the tear film results in pain, itching, blurry vision, and dryness, among other symptoms.

  • PR Newswire7 days ago

    First Patient Enrolled in RegeneRx JV Phase 3 Dry Eye Trial

    ROCKVILLE, Md., May 13, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patient has been enrolled in ARISE-3, a phase 3 clinical trial sponsored by ReGenTree LLC, a U.S. joint venture between RegeneRx and GtreeBNT, a Korean biopharmaceutical company.  The clinical trial will evaluate RGN-259, a sterile, preservative-free eye drop in 700 patients with dry eye syndrome (DES) at approximately fifteen nationwide clinical sites across the U.S., including hospitals and clinics specializing in ophthalmology, comparing the drug candidate to placebo.  Completion is expected during mid-2020. Additional information may be found at  clinicaltrials.gov/ct2/show/NCT03937882?term=arise-3&rank=1.

  • PR Newswire28 days ago

    RegeneRx Publishes Annual Letter to Shareholders

    ROCKVILLE, Md., April 22, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published its annual letter to stockholders on the Company's website at www.regenerx.com. Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

  • PR Newswire2 months ago

    RegeneRx to Present at 2019 Spring Investor Summit

    ROCKVILLE, Md., March 27, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Spring Investor Summit taking place on April 1-2, 2019 in New York, NY.  Mr. Finkelstein will speak on Tuesday, April 2 at 9:00 a.m. ET.  A copy of his presentation will be available on the Company's website at http://www.regenerx.com/presentations on Tuesday morning. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world.

  • PR Newswire2 months ago

    RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China

    ROCKVILLE, Md. and HONG KONG, March 26, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited ("Lee's Pharm"), a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications.  Lee's Pharm previously licensed RGN-259, RegeneRx's sterile, preservative-free, topical eye drop developed for the treatment of ophthalmic indications such as dry eye syndrome (DES), neurotrophic keratitis (NK), and other persistent corneal disorders, in China, Taiwan, Macau, and Hong Kong.

  • PR Newswire2 months ago

    RegeneRx Announces New Board Member

    ROCKVILLE, Md., March 21, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the appointment of Alessandro Noseda M.D. to the Company's Board of Directors, effective April 1, 2019.  He will be the sixth member of the Company's Board. Dr. Noseda is the Chief Scientific Officer of Leadiant Biosciences S.p.A. and has extensive scientific and medical experience in the global development of new medical technologies and drug products.  He has held numerous managerial positions with the R&D and marketing organizations of multinational pharmaceutical companies during his career.  Previously, Dr. Noseda was the Director of Scientific Office and Strategic Alliances with Sigma-Tau, where he managed key R&D projects and was involved in creating partnerships with Novartis and Debiopharm, among others.

  • PR Newswire3 months ago

    RegeneRx Closes $1.3 Million Convertible Debt Financing

    ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $1.3 million convertible debt financing.  The funds will be used for operations over the next approximately 12 months while a phase 3 dry eye trial (ARISE-3), phase 3 neurotrophic keratitis trial (SEER-1), and epidermolysis bullosa open study are being conducted by its partner and licensee.

  • PR Newswire3 months ago

    RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259

    ROCKVILLE, Md., Feb. 12, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, has executed an agreement with Ora, Inc., located in Andover, Massachusetts, for initiation of ARISE-3 to study ReGenTree's new drug, RGN-259, a sterile, preservative-free eye drop for the treatment of dry eye syndrome. ARISE-3 is a randomized double-masked, placebo-controlled phase 3 clinical trial that is based on the results of previous clinical trials, ARISE-1 and ARISE-2.

  • PR Newswire4 months ago

    RegeneRx Update on Dry Eye and EB Clinical Trials

    ROCKVILLE, Md. , Jan. 4, 2019 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...

  • PR Newswire7 months ago

    RegeneRx Partner Updates on Clinical Trials

    "Regarding progress on ARISE-3, the manufacturing of the investigational product for ARISE-3 has been completed and the protocol for the study has been finalized and is now ready for the study. Also, since funding for the ARISE-3 clinical study is progressing smoothly towards the final stage, we will do our best to inform you of ARISE-3 study initiation as soon as possible.

  • PR Newswire8 months ago

    World Health Organization Recommends INN for Thymosin Beta 4 as "timbetasin"

    ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the recommended INN (International Nonproprietary Name) for Thymosin Beta 4 is timbetasin, as published by the World Health Organization (WHO). The term "INN" is an official name given to a new active pharmaceutical ingredient as prescribed by the WHO and is given for the classification of substances. Any drug substance that has the characteristics of "Thymosin beta 4" that will be developed as a pharmaceutical product in the future must use the name "timbetasin", a term requested by GtreeBNT.  The common name, "timbetasin," was designated according to the guidelines for WHO INN naming and has a symbolic meaning that can be associated with Thymosin Beta 4.

  • PR Newswire10 months ago

    RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa

    ROCKVILLE, Md., Aug. 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT, has entered into a joint venture with YuYang DNU, a Korean company, to develop RGN-137 on a global basis for the orphan indication, epidermolysis bullosa (EB).  The joint venture between the two companies is Lenus Therapeutics, LLC (Lenus), a GtreeBNT U.S. subsidiary.  Gtree will contribute the intellectual property rights and all development results for RGN-137 and YuYang will invest about $17.8 million in cash into Lenus. According to GtreeBNT's press release, prior to a Phase 3 study planned for next year, Lenus is first planning to conduct an open study to attract big pharma, which has expressed ongoing interest in the product.  The Phase 3 trial is then expected to enroll approximately 200 subjects around the world, including in the U.S.

  • PR Newswire10 months ago

    RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugs in Dry Eye Model

    The study was published on July 12, 2018, in the journal, Scientific Reports, an online open access scientific mega journal and part of the Nature Publishing Group.  The study was conducted by researchers who are either consultants to RegeneRx or, employees of, or consultants to GtreeBNT/ReGenTree LLC, a RegeneRx licensee for RGN-259 in North American and certain Asian territories.  Some of the study data were previously presented at the 2018 ARVO meeting in May 2018. RGN-259 is currently in Phase 3 clinical trials in the U.S. and been studied in approximately 1,000 patients.  In addition to the reported rapid onset of clinical efficacies, RGN-259 has not reported any significant side effects compared to other products currently approved for DES.

  • PR Newswire11 months ago

    RegeneRx Holds Annual Meeting

    ROCKVILLE, Md. , June 13, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)   ("the Company" or "RegeneRx"), today held its 2018 Annual Meeting.  Seventy-eight of ...

  • PR Newswirelast year

    RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018

    ROCKVILLE, Md. , May 29, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today is correcting a misprinted annual meeting date in ...